http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 22 May 2025 16:05:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+%28OTLK%29+propses+public+offering+/24840672.html <p><strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p><p align="justify">Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+%28OTLK%29+propses+public+offering+/24840672.html Thu, 22 May 2025 16:05:37 -0400 OTLK OTLKW http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+%28OTLK%29+propses+public+offering+/24840672.html <p><strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p><p align="justify">Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general http://www.streetinsider.com/Equity+Offerings/Outlook+Therapeutics+%28OTLK%29+propses+public+offering+/24840672.html Thu, 22 May 2025 16:05:37 -0400 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html <p align="justify">ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- <strong>Outlook Therapeutics, Inc.</strong> (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</p> <p align="justify">Outlook Therapeutics intends to use the net http://www.streetinsider.com/Globe+Newswire/Outlook+Therapeutics%C2%AE+Announces+Proposed+Public+Offering+of+Common+Stock+and+Warrants/24840500.html Thu, 22 May 2025 16:01:00 -0400 A.06822034 A.28803699 A.60012004 O.01304637 O.14475130 O.20026344 OTLK OTLKW http://www.streetinsider.com/Corporate+News/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html <p><span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow">Outlook Therapeutics, Inc.</span> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA™ (bevacizumab gamma), as an option for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU http://www.streetinsider.com/Corporate+News/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html Wed, 04 Dec 2024 08:06:04 -0400 OTLK OTLKW http://www.streetinsider.com/Corporate+News/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html <p><span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow">Outlook Therapeutics, Inc.</span> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA™ (bevacizumab gamma), as an option for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU http://www.streetinsider.com/Corporate+News/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html Wed, 04 Dec 2024 08:06:04 -0400 OTLK OTLKW http://www.streetinsider.com/FDA/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html <p><span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow">Outlook Therapeutics, Inc.</span> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA™ (bevacizumab gamma), as an option for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU http://www.streetinsider.com/FDA/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html Wed, 04 Dec 2024 08:06:04 -0400 OTLK OTLKW http://www.streetinsider.com/FDA/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html <p><span data-silink="1" target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow">Outlook Therapeutics, Inc.</span> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA™ (bevacizumab gamma), as an option for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU http://www.streetinsider.com/FDA/Outlook+Therapeutics+%28OTLK%29+Announces+NICE+Recommendation+of+LYTENAVA+for+the+Treatment+of+Wet+AMD/24064028.html Wed, 04 Dec 2024 08:06:04 -0400 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html <p align="center"><em>First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025</em></p> <p align="center"><em>LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)</em></p> <p align="center"><em>40,000 new wet AMD patients each year in the UK who could benefit from treatment</em><em>1</em></p> <p align="justify">ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html Wed, 04 Dec 2024 08:05:00 -0400 A.03186153 A.32537045 A.60012004 A.60012009 O.05014938 O.14475130 O.50921235 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html <p align="center"><em>First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025</em></p> <p align="center"><em>LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)</em></p> <p align="center"><em>40,000 new wet AMD patients each year in the UK who could benefit from treatment</em><em>1</em></p> <p align="justify">ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html Wed, 04 Dec 2024 08:05:00 -0400 A.03186153 A.32537045 A.60012004 A.60012009 O.05014938 O.14475130 O.50921235 OTLK OTLKW http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html <p align="center"><em>First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025</em></p> <p align="center"><em>LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)</em></p> <p align="center"><em>40,000 new wet AMD patients each year in the UK who could benefit from treatment</em><em>1</em></p> <p align="justify">ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=DuF6kZC4lU5zKAIFNA__yvPjoLDwr0HJQPigB2Zi7xYMbo3b3R_948bAPRufkHnhQQRdq1w-N9bkxFtrme7Ba_-us8JW0HgbWr1stDV-2Nghe5WQXjVrGQ-aXdiOrQrG" rel="nofollow" target="_blank">Outlook Therapeutics, Inc.</a> (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ http://www.streetinsider.com/Press+Releases/Outlook+Therapeutics%C2%AE+Announces+NICE+Recommendation+of+LYTENAVA%E2%84%A2+%28bevacizumab+gamma%29+for+the+Treatment+of+Wet+AMD/24064025.html Wed, 04 Dec 2024 08:05:00 -0400 A.03186153 A.32537045 A.60012004 A.60012009 O.05014938 O.14475130 O.50921235 OTLK OTLKW